Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109931 | 0.91 | CA12 (0.42) | PLK1TP53S1PR1S1PR3S1PR4 | |
| SCHEMBL21799295 | 0.81 | CA12 (0.47) | PLK1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL18109936 | 0.81 | CA12 (0.50) | PLK1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL15888157 | 0.81 | MEN1 (0.47) | FAAHTSHRCNR2 | |
| Iodide SCHEMBL16742380 | 0.79 | CHRNA7 (0.46) | CNR2 | |
| SCHEMBL29022674 | 0.79 | FAAH (0.66) | FAAH | |
| SCHEMBL6758311 | 0.79 | FAAH (0.66) | FAAH | |
| SCHEMBL28155109 | 0.76 | CNR2 (0.43) | PLK1CNR2 | |
| SCHEMBL16756051 | 0.76 | MAPT (0.53) | PLK1TP53TSHR | |
| SCHEMBL18109928 | 0.75 | CHRNA7 (0.40) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071582-B1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | RES & INNOVATION UK (GB) | 2020-04-29 | — | — | EP | disclosed |
| EP-3623375-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | United Kingdom Research and Innovation (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-9963474-B2 | Mitochondria-targeted dicarbonyl sequestering compounds | MEDICAL RESEARCH COUNCIL (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160289252-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289252-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | NDUFAB1, HADHB, SLC25A21 | PLK1 3990/4885FAAH 3758/4885TP53 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.